PortfoliosLab logoPortfoliosLab logo
TSHA vs. ATRO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TSHA vs. ATRO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Taysha Gene Therapies, Inc. (TSHA) and Astronics Corporation (ATRO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TSHA achieves a 18.73% return, which is significantly lower than ATRO's 89.08% return.


TSHA

1D
1.71%
1M
18.94%
YTD
18.73%
6M
11.43%
1Y
165.45%
3Y*
114.68%
5Y*
-23.63%
10Y*

ATRO

1D
1.60%
1M
26.83%
YTD
89.08%
6M
84.09%
1Y
210.12%
3Y*
77.18%
5Y*
41.67%
10Y*
13.83%
*Multi-year figures are annualized to reflect compound growth (CAGR)

TSHA vs. ATRO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
TSHA
Taysha Gene Therapies, Inc.
18.73%217.92%-2.26%-21.68%-80.60%-56.10%19.28%
ATRO
Astronics Corporation
89.08%239.85%-8.38%69.13%-14.17%-9.30%67.47%

Correlation

The correlation between TSHA and ATRO is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.32

Correlation (3Y)
Calculated over the trailing 3-year period

0.18

Correlation (5Y)
Calculated over the trailing 5-year period

0.18

Correlation (All Time)
Calculated using the full available price history since Sep 24, 2020

0.18

The correlation between TSHA and ATRO shifts across timeframes, from 0.18 (5 years) to 0.32 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

TSHA:

$2.39B

ATRO:

$3.13B

EPS

TSHA:

-$0.39

ATRO:

$1.22

PS Ratio

TSHA:

292.29

ATRO:

3.43

PB Ratio

TSHA:

11.30

ATRO:

19.35

Total Revenue (TTM)

TSHA:

$7.47M

ATRO:

$886.81M

Gross Profit (TTM)

TSHA:

$6.89M

ATRO:

$272.44M

EBITDA (TTM)

TSHA:

-$130.51M

ATRO:

$74.47M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TSHA vs. ATRO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TSHA
TSHA Risk / Return Rank: 8989
Overall Rank
TSHA Sharpe Ratio Rank: 8787
Sharpe Ratio Rank
TSHA Sortino Ratio Rank: 9090
Sortino Ratio Rank
TSHA Omega Ratio Rank: 8686
Omega Ratio Rank
TSHA Calmar Ratio Rank: 9393
Calmar Ratio Rank
TSHA Martin Ratio Rank: 8989
Martin Ratio Rank

ATRO
ATRO Risk / Return Rank: 9696
Overall Rank
ATRO Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
ATRO Sortino Ratio Rank: 9595
Sortino Ratio Rank
ATRO Omega Ratio Rank: 9494
Omega Ratio Rank
ATRO Calmar Ratio Rank: 9797
Calmar Ratio Rank
ATRO Martin Ratio Rank: 9898
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TSHA vs. ATRO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Taysha Gene Therapies, Inc. (TSHA) and Astronics Corporation (ATRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TSHAATRODifference
Sharpe ratioReturn per unit of total volatility

-1.89

Sortino ratioReturn per unit of downside risk

-0.78

Omega ratioGain probability vs. loss probability

1.36

1.53

-0.17

Calmar ratioReturn relative to maximum drawdown

5.35

9.04

-3.70

Martin ratioReturn relative to average drawdown

11.14

31.21

-20.07

TSHA vs. ATRO - Sharpe Ratio Comparison

The current TSHA Sharpe Ratio is 1.91, which is lower than the ATRO Sharpe Ratio of 3.79. The chart below compares the historical Sharpe Ratios of TSHA and ATRO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

TSHA vs. ATRO - Drawdown Comparison

The maximum TSHA drawdown since its inception was -98.14%, which is greater than ATRO's maximum drawdown of -90.12%. Use the drawdown chart below to compare losses from any high point for TSHA and ATRO.


Loading charts...

Drawdown Indicators


TSHAATRODifference

Max Drawdown

Largest peak-to-trough decline

-98.14%

-90.12%

-8.02%

Max Drawdown (1Y)

Largest decline over 1 year

-31.13%

-23.39%

-7.74%

Max Drawdown (3Y)

Largest decline over 3 years

-72.90%

-34.89%

-38.01%

Max Drawdown (5Y)

Largest decline over 5 years

-97.76%

-60.47%

-37.29%

Max Drawdown (10Y)

Largest decline over 10 years

-85.52%

Current Drawdown

Current decline from peak

-79.43%

0.00%

-79.43%

Average Drawdown

Average peak-to-trough decline

-76.85%

-38.06%

-38.79%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.91%

6.76%

+8.15%

Volatility

TSHA vs. ATRO - Volatility Comparison

The current volatility for Taysha Gene Therapies, Inc. (TSHA) is 15.00%, while Astronics Corporation (ATRO) has a volatility of 19.02%. This indicates that TSHA experiences smaller price fluctuations and is considered to be less risky than ATRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TSHAATRODifference

Volatility (1M)

Calculated over the trailing 1-month period

15.00%

19.02%

-4.02%

Volatility (6M)

Calculated over the trailing 6-month period

49.27%

39.42%

+9.85%

Volatility (1Y)

Calculated over the trailing 1-year period

87.56%

55.91%

+31.65%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

136.69%

55.12%

+81.57%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

130.29%

56.92%

+73.37%

Dividends

TSHA vs. ATRO - Dividend Comparison

Neither TSHA nor ATRO has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

TSHA vs. ATRO - Financials Comparison

This section allows you to compare key financial metrics between Taysha Gene Therapies, Inc. and Astronics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M202220232024202520260
230.62M
(TSHA) Total Revenue
(ATRO) Total Revenue
Values in USD except per share items

Frequently Asked Questions


TSHA and ATRO have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ATRO has higher volatility (19.02%) compared to TSHA (15.00%). In terms of maximum drawdown, TSHA dropped -98.14% vs ATRO's -90.12%.

ATRO currently has the higher Sharpe Ratio (3.79 vs 1.91), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TSHA and ATRO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer